Musacchio Thomas, Rebenstorff Maike, Fluri Felix, Brotchie Jonathan M, Volkmann Jens, Koprich James B, Ip Chi Wang
Department of Neurology, University Hospital of Würzburg, Würzburg, Germany.
The Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
Ann Neurol. 2017 Jun;81(6):825-836. doi: 10.1002/ana.24947. Epub 2017 Jun 9.
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a highly effective symptomatic therapy for motor deficits in Parkinson's disease (PD). An additional, disease-modifying effect has been suspected from studies in toxin-based PD animal models, but these models do not reflect the molecular pathology and progressive nature of PD that would be required to evaluate a disease-modifying action. Defining a disease-modifying effect could radically change the way in which DBS is used in PD.
We applied STN-DBS in an adeno-associated virus (AAV) 1/2-driven human mutated A53T α-synuclein (aSyn)-overexpressing PD rat model (AAV1/2-A53T-aSyn). Rats were injected unilaterally, in the substantia nigra (SN), with AAV1/2-A53T-aSyn or control vector. Three weeks later, after behavioral and nigrostriatal dopaminergic deficits had developed, rats underwent STN-DBS electrode implantation ipsilateral to the vector-injected SN. Stimulation lasted for 3 weeks. Control groups remained OFF stimulation. Animals were sacrificed at 6 weeks.
Motor performance in the single pellet reaching task was impaired in the AAV1/2-A53T-aSyn-injected stim-OFF group, 6 weeks after AAV1/2-A53T-aSyn injection, compared to preoperative levels (-82%; p < 0.01). Deficits were reversed in AAV1/2-A53T-aSyn, stim-ON rats after 3 weeks of active stimulation, compared to the AAV1/2-A53T-aSyn stim-OFF rats (an increase of ∼400%; p < 0.05), demonstrating a beneficial effect of DBS. This motor improvement was maintained when the stimulation was turned off and was accompanied by a higher number of tyrosine hydroxylase SN neurons (increase of ∼29%), compared to AAV1/2-A53T-aSyn stim-OFF rats (p < 0.05).
Our data support the putative neuroprotective and disease-modifying effect of STN-DBS in a mechanistically relevant model of PD. Ann Neurol 2017;81:825-836.
丘脑底核(STN)的深部脑刺激(DBS)是帕金森病(PD)运动功能障碍的一种高效对症治疗方法。基于毒素的PD动物模型研究曾怀疑其具有额外的疾病修饰作用,但这些模型无法反映评估疾病修饰作用所需的PD分子病理学及疾病进展特性。明确疾病修饰作用可能会从根本上改变DBS在PD治疗中的应用方式。
我们在腺相关病毒(AAV)1/2驱动的人突变A53T α-突触核蛋白(aSyn)过表达的PD大鼠模型(AAV1/2-A53T-aSyn)中应用STN-DBS。大鼠单侧黑质(SN)注射AAV1/2-A53T-aSyn或对照载体。三周后,在行为和黑质纹状体多巴胺能缺陷出现后,大鼠在注射载体的SN同侧植入STN-DBS电极。刺激持续3周。对照组不进行刺激。6周时处死动物。
与术前水平相比,AAV1/2-A53T-aSyn注射后刺激关闭组在单颗粒抓取任务中的运动表现受损(-82%;p<0.01)。与AAV1/2-A53T-aSyn刺激关闭组相比,AAV1/2-A53T-aSyn刺激开启组在主动刺激3周后,缺陷得到逆转(增加约400%;p<0.05),表明DBS具有有益作用。当刺激关闭时,这种运动改善得以维持,并且与AAV1/2-A53T-aSyn刺激关闭组相比,酪氨酸羟化酶SN神经元数量更多(增加约29%)(p<0.05)。
我们的数据支持STN-DBS在与机制相关的PD模型中具有假定的神经保护和疾病修饰作用。《神经病学纪要》2017年;81:825 - 836。